[Therapeutic results with aclacinomycin A in recurring acute leukemias].
21 patients with relapsing or primarily chemotherapy resistant acute myeloid or lymphocytic leukemia were treated with Aclacinomycin A (ACM). 25 mg/m2 ACM were given i.v. daily for 7 consecutive days. 17 out of 21 patients are evaluable, 2 with acute lymphocytic and 15 with acute myeloid leukemia. Two of the patients with acute myeloid leukemia entered complete remission. A further patient, primarily resistant to adriamycin and daunorubicin, experienced a partial remission. None of the patients with ALL responded to ACM.
D015250:Aclarubicin / Q000031:analogs & derivatives*; D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000008:administration & dosage; D012008:Recurrence
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; C011157:aclacinomycins; D015250:Aclarubicin
Therapieergebnisse mit Aclacinomycin A bei rezidivierten akuten Leukämien.